EGFR and Guillain-Barre syndrome: In retrospective analyses of phase 2 and 3 clinical trials for the first line treatment of GBs, mTOR activation as assessed by IHC was identified as a biomarker to predict response to mTOR (Wick et al. 2016) or EGFR inhibitors [13, 14, 70].